MDACC 2018: Debate: Is There Still a Role for Cytoreductive Nephrectomy in the Setting of Metastatic Renal Cell Carcinoma?
Dr. Jose Karam explains the role of cytoreductive nephrectomies when patients have metastatic kidney cancer.11/12/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 12, 2018 Category: Urology & Nephrology Source Type: news
MDACC 2018: Systemic Therapy for Metastatic Non-Clear Cell Histology Patients: What Works and What Doesn ât?
Our 2017 YIA winner Pavlos Msaouel is doing great work in kidney cancer research. In this article, he explains chemotherapy vs. targeted therapies.11/12/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 12, 2018 Category: Urology & Nephrology Source Type: news
Systemic Therapy Options for Renal Cell Carcinoma
Monty Pal and Charles Ryan discuss systemic therapeutic options and current clinical trials in the renal cell carcinoma space.11/09/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 9, 2018 Category: Urology & Nephrology Source Type: news
Trends in Renal-Cell Carcinoma Incidence and Mortality in the United States in the Last 2 Decades: A SEER-Based Study
Despite an overall increase in the incidence of RCC, there has been a recent plateau in RCC incidence rates with a significant decrease in mortality.11/09/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 9, 2018 Category: Urology & Nephrology Source Type: news
Personalized Immunotherapy Combinations on Horizon
Future development of novel immunotherapy combinations should be based on individual patient characteristics, such as patient-level immune targets and tumor microenvironment, according to a presentation by Jason Luke, MD, at the 36th Annual CFS.11/09/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 9, 2018 Category: Urology & Nephrology Source Type: news
Sunitinib Alone or after Nephrectomy in Renal Cancer
In the CARMENA (Cancer du Rein Metastatique Nephrectomie et Antiangiog éniques) trial, Méjean et al. (Aug. 2 issue)1 determine the noninferiority of sunitinib alone, as compared with nephrectomy followed by sunitinib, on the basis of the observation that the 95% confidence interval for the hazard ratio of death did not exceed 1.20 (the noninferiority margin for t he trial).11/09/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 9, 2018 Category: Urology & Nephrology Source Type: news
Potential clinical applications of microRNAs as biomarkers for renal cell carcinoma
Renal cell carcinoma (RCC) accounts for 3% of adult malignancies and more than 90% of kidney neoplasms. High rates of undiagnostic percutaneous kidney biopsies and difficulties in reliable pre-operative differentiation between malignant and benign renal tumors using contemporary imaging techniques result in large numbers of redundant surgeries.11/08/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 8, 2018 Category: Urology & Nephrology Source Type: news
Front-Line Combo Found Superior for Advanced RCC
Avelumab plus axitinib combination therapy is associated with better outcomes compared with sunitinib alone as first-line treatment of advanced renal cell carcinoma (RCC), according to study findings presented at the European Society for Medical Oncology 2018 Congress in Munich, Germany.11/08/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 8, 2018 Category: Urology & Nephrology Source Type: news
Distress Levels High Among Patients With Common Form of Kidney Cancer
Many patients with renal cell carcinoma, the most common type of kidney cancer, experience high levels of distress, according to study findings published in BJU International.11/08/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 8, 2018 Category: Urology & Nephrology Source Type: news
Surgical Management of Advanced Kidney Cancer: The Role of Cytoreductive Nephrectomy and Lymphadenectomy
Despite the evolution of systemic therapy from the immunotherapy to targeted therapy eras, surgical management remains a mainstay of treatment of patients with locally advanced, lymph node-positive, and distant metastatic renal cell carcinoma.11/07/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 7, 2018 Category: Urology & Nephrology Source Type: news
Non-Coding Micro RNAs and Hypoxia-Inducible Factors Are Selenium Targets for Development of a Mechanism-Based Combination Strategy in Clear-Cell Renal Cell Carcinoma-Bench-to-Bedside Therapy
Durable response, inherent or acquired resistance, and dose-limiting toxicities continue to represent major barriers in the treatment of patients with advanced clear-cell renal cell carcinoma (ccRCC).11/07/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 7, 2018 Category: Urology & Nephrology Source Type: news
Comprehensive assessment gene signatures for clear cell renal cell carcinoma prognosis
There are many prognostic gene signature models in clear cell renal cell carcinoma (ccRCC). However, different results from various methods and samples are hard to contribute to clinical practice. It is necessary to develop a robust gene signature for improving clinical practice in ccRCC. A method was proposed to integrate least absolute shrinkage and selection operator and multiple Cox regression to obtain mRNA and microRNA signature from the cancer genomic atlas database for predicting prognosis of ccRCC.11/07/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 7, 2018 Category: Urology & Nephrology Source Type: news
Tivozanib Improves PFS in Highly Refractory RCC
The VEGF inhibitor tivozanib (Fotivda) reduced the risk of disease progression or death by 26% compared with sorafenib (Nexavar) in patients with highly refractory advanced or metastatic renal cell carcinoma (RCC), according to topline findings from the phase III TIVO-3 trial.11/07/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 7, 2018 Category: Urology & Nephrology Source Type: news
Limiting protein intake may enhance response to immunotherapy
Restricting protein intake may improve responses to immunotherapy, according to study results published in Clinical Cancer Research.11/07/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 7, 2018 Category: Urology & Nephrology Source Type: news
Tivozanib extends PFS in advanced renal cell carcinoma
Tivozanib extended PFS compared with sorafenib among patients with highly refractory advanced or metastatic renal cell carcinoma, according to randomized phase 3 study results released by the agent âs manufacturer.11/07/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 7, 2018 Category: Urology & Nephrology Source Type: news
